The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia

Expert Opinion on Drug Safety

Volumn 6, Issue 6, 2007, Pages 651-662

  Spina, Edoardo ^a,b   Cavallaro, Roberto ^c  

^a UNIVERSITY OF MESSINA   (Italy)

^b IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Antipsychotics; Extrapyramidal symptoms; Paliperidone; Prolactin level; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CARBAMAZEPINE; CLOZAPINE; FLUOXETINE; ITRACONAZOLE; OLANZAPINE; PALIPERIDONE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; 9 HYDROXY RISPERIDONE; 9-HYDROXY-RISPERIDONE; ISOXAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

AKATHISIA; AMENORRHEA; ANORGASMIA; ANXIETY; CARDIOTOXICITY; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED RELEASE FORMULATION; DIZZINESS; DOSE KIDNEY FUNCTION RELATION; DOSE TIME EFFECT RELATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG WITHDRAWAL; DYSTONIA; ECG ABNORMALITY; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HEADACHE; HUMAN; HYPERKINESIA; HYPERPROLACTINEMIA; HYPERSALIVATION; IMPOTENCE; INSOMNIA; INSULIN BLOOD LEVEL; LACTATION; LIBIDO DISORDER; LIPOPROTEIN BLOOD LEVEL; MAXIMUM PLASMA CONCENTRATION; MENSTRUAL IRREGULARITY; METABOLIC DISORDER; MONOTHERAPY; MOTOR DYSFUNCTION; MUSCLE HYPERTONIA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PATIENT SAFETY; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL FUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; TARDIVE DYSKINESIA; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; METABOLISM; TREATMENT OUTCOME;

ANIMALS; DELAYED-ACTION PREPARATIONS; HUMANS; ISOXAZOLES; PYRIMIDINES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 38449090708     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.6.651     Document Type: Review

References (54)

1. STAHL S: Essential psychopharmacology of antipsychotics and mood stabiiizers. Cambridge university press, Cambridge, UK (2002).
2. NEWCOMER JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs (2005) 19(Suppl. 1):1-93.
3. YANG LPH, PLOSKER GL: Paliperidone extended release. CNS Drugs (2007) 21:417-425.
4. OWEN RT. Extended-release paliperidone: efficacy, safety and tolerability profile of a new antipsychotic. Drugs Today (2007) 43:249-258.
5. CITROME L: Paliperidone: quo vadis? Int. J. Clin. Pract. (2007) 61:653-662.
6. NO AUTHORS LISTED: Paliperidone (Invega) for schizophrenia. Med. Lett. Drugs Ther. (2007) 49:21.
7. KANE J, CANAS F, KRAMER M et al.: Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr. Res. (2007) 90:147-161.
8. DAVIDSON M, EMSLEY R, KRAMER M et al.: Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER). Results of a 6-week, randomized, placebo-controlled study. Schizophr. Res. (2007) 93:117-130.
9. MARDER SR, KRAMER M, FORD L et al.: Efficacy and safety of paliperidone extended-release tablets. Results of a 6-week, randomized, placebo-controlled study. Biol. Psychiatry (2007) (In Press).
10. KRAMER M, SIMPSON G, MACIULIS V et al.: Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. (2007) 27:6-14.
11. INVEGA (PALIPERIDONE) EXTENDED-RELEASE TABLETS: Prescribing information. Janssen LP, Titusville, NJ, USA (2006).
12. CONLEY R, GUPTA SK, SATHYAN G: Clinical spectrum of the osmotic-controlled release oral delivery system (OROS*), an advanced oral delivery form. Curr. Med. Res. Opin. (2006) 22:1879-1892.
13. KEITH S: Advances in psychotropic formulations. Prog. NeuroPsychopharmacol. Biol. Psychiatry (2006) 30:996-1008.
14. BASS DM, PREVO M, WAXMAN DS: Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS): a retrospective study. Drug Saf. (2002) 25:1021-1033.
15. MEGENS AA, AWOUTERS FH, SCHOTTE A et al.: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (1994) 114:9-23.
16. LEYSEN JE, JANSSEN PM, MEGENS AA, SCHOTTE A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry (1994) 55(Suppl.):5-12.
17. SCHOTTE A, JANSSEN PF, GOMMEREN W et al.: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (1996) 124:57-73.
18. SEEMAN P: An update of fast-off dopamine D2 atypical antipsychotics. Am. J. Psychiatry (2005) 162:1984-1985.
19. BOWDEN CR, VOINA SJ, WOESTENBORGHS R, DE COSTER R, HEYKANTS J: Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro. J Pharmacol Exp. Ther. (1992) 262:699-706.
20. 2A receptor occupancy and safety profile of paliperidone ER in healthy subjects. Schizophr. Res. (2006) 81(Suppl. 1):85-86.
21. HUANG ML, VAN PEER A, WOESTENBORGHS R et al.: Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin. Pharmacol. Ther. (1993) 54:257-268.
22. FANG J, BOURIN M, BAKER GB: Metabolism of risperidone to 9-hydroxyrisperidone by human cytochrome P450 2D6 and 3A4. NaunynSchmiederberg's Arch. Pharmacol. (1999) 359:147-151.
23. YASUI-FURUKORI N, HIDESTRAND M, SPINA E, FACCIOLÁ G, SCORDO MG, TYBRING G: Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab. Dispos. (2001) 29:1263-1268.
24. SCORDO MG, SPINA E, FACCIOLÁ G, AVENOSO A, JOHANSSON I, DAHL ML: Cytochrome P450 2D6 genotype and steady-state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (1999) 147:300-305.
25. ROSSENU S, CRAUWELS H, CLETON A et al.: Evaluation of the pharmacokinetics of several formulations of paliperidone. AAPS J. (2006) 8(Suppl. 2): Abstract M1371.
26. CLETON A, ROSSENU S, TALLURI K et al.: Evaluation of the pharmacokinetics of an extended-release formulation of paliperidone and an immediate-release formulation of risperidone. Clin. Pharmacol. Ther. (2007) 81(Suppl. 1):S63.
27. ROSSENU S, CRAUWELS H, CLETON A et al.: Extended-release formulation of paliperidone shows dose proportional pharmacokinetics. AAPS J. (2006) 8(Suppl. 2): Abstract T3123.
28. VAN BEIJSTERVELDT LE, GEERTS RJ, LEYSEN JE et al.: Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (1994) 114:53-62.
29. ARAVAGIRI M, YUWILER A, MARDER SR: Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Pychopharmacology (1998) 139:356-363.
30. ARAVAGIRI M, MARDER SR, Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology (2002) 159:424-431.
31. WANG JS, RUAN Y, TAYLOR RM, DONOVAN JL, MARKOWITZ JS, DE VANE CL: The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int. J. Neuropsychopharmacol. (2004) 7:415-419.
32. EJSING TB, PEDERSEN AD, LINNET K: P-glycoprotein interaction with risperidone and 9-OH-rispefidone studied in vitro, in knock-out mice and in drug - drug interaction experiments. Hum. Psychopharmacol. (2005) 20:493-500.
33. DORAN A, OBACH RS, SMITH BJ et al.: The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab. Dispos. (2005) 33:165-174.
34. 14C-paliperidone 1 mg in healthy subjects. Eur. Neuropsychopharmacol. (2006) 30:S191-S192.
35. THYSSEN A, CRAUWELS H, CLETON A et al.: Effects of hepatic impairment on the pharmacokinetics of paliperidone. 46th Annual Meeting New Clinical Drug Evaluation Unit, Boca Raton, Florida, USA (2006) (Abstract n. I-90).
36. THYSSEN A, CLETON A, VAN OSSELAER N et al.: Effects of renal impairment on the pharmacokinetic profile of paliperidone extended-release tablets. Clin. Pharmacol. Ther. (2007) 81(Suppl. 1):S63.
37. ROSSENU S, CLETON A, BOOM S, ALNABAWY A, TALLURI K, EERDEKENS M: Evaluation of the pharmacokinetics of paliperidone extended-release tablets in healthy elderly subjects. Clin. Pharmacol. Ther. (2007) 81(Suppl. 1):S64.
38. SPINA E, DE LEON J: Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin. Pharmacol. Toxicol. (2007) 100:4-22.
39. CLETON A, BERWAERTS J, VAN DE VLIET I et al.: A randomized, open-label, single-center, crossover study of the potential effects of paroxetine on the pharmacokinetics of a single dose of paliperidone extended-release tablets in healthy subjects. 160th Annual Meeting APA, San Diego, California, USA (2007): (Abstract NR500).
40. SPINA E, AVENOSO A, SCORDO MG et al.: Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J. Clin. Psychopharmacol. (2002) 22:419-423.
41. SPINA E, AVENOSO A, FACCIOLÁ G, SCORDO MG, ANCIONE M, MADIA A: Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther. Drug Monit. (2001) 23:223-227.
42. SAITO M, YASUI-FURUKORI N, NAKAGAMI T, FURUKORI H, KANEKO S: Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J. Clin. Psychopharmacol. (2005) 25:527-532.
43. JUNG SM, KIM KA, CHO HK et al.: Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin. Pharmacol. Ther. (2005) 78:520-528.
44. SPINA E, AVENOSO A, FACCIOLÁ G et al.: Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther. Drug Monit. (2000) 22:481-485.
45. ONO S, MIHARA K, SUZUKI A, KONDO T et al.: Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology (2002) 162:50-54.
46. WANG JS, ZHU HJ, MARKOWITZ JS, DONOVAN JL, DE VANE CL: Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (2006) 187:415-423.
47. ZHU HJ, WANG JS, MARKOWITZ JS, DONOVAN JL, GIBSON BB, DE VANE CL: Risperidone and paliperidone inhibit P-glycoprotein activity in vitro. Neuropsychopharmacology (2007) 32:757-764.
48. EERDEKENS M, KRAMER M, MARTINEZ L, LANE R, LIM P, CANUSO C: Efficacy and tolerability of oral paliperidone extended release tablets in the treatment of acute schizophrenia: pooled data from three 52-week, open label extension studies. 11th International Congress on Schizophrenia Research, Colorado Springs, Colorado, USA. Schizophr. Bull. (2007) 33:429.
49. KNEGTERING R, BASELMANS P, CASTELEIN S, BOSKER F, BRUGGEMAN R, VAN DEN BOSCH RJ: Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am. J. Psychiatry (2005) 162:1010-1012.
50. MELKERSSON KI: Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum. Psychopharmacol. (2006) 21:529-532.
51. PANDINA GJ, CANUSO CM, YOUSSEF E, KUJAWA M, MAHMOUD R: Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia. Hum. Psychopharmacol. (2007) 22:326-327.
52. MELKERSSON KI: Author's response. Hum. Psychopharmacol. (2007) 22:328.
53. KRAMER M, EERDEKENS M, LANE R, LIM P, SHERR J, PALUMBO J: Metabolic outcomes in terms of weight, glucose and lipid profiles in patients with schizophrenia treated with paliperidone extended-release for 52 weeks, 160th Annual Meeting APA, San Diego, California, USA (2007): Abstract NR498.
54. TZIMOS A, KRAMER M, FORD L, GASSMANN-MEYER. C, LIM P, EERDEKENS M: A 6-week placebo-controlled study of the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients. Int. J. Neurophychopharmacol. (2006) 9:S155.